Title:
PRODRUG INTENDED FOR THE TREATMENT OF BACTERIAL INFECTIONS RESISTANT TO ANTIBIOTICS OF THE BETA-LACTAM FAMILY
Document Type and Number:
WIPO Patent Application WO/2023/203187
Kind Code:
A1
Abstract:
The invention relates to the field of antibacterial treatments intended to combat antibiotic-resistant infections. The invention relates more particularly to a prodrug that makes it possible to locally and specifically inhibit a bacterial infection due to a bacterium resistant to antibiotics of the beta-lactam family. This prodrug comprises an antibacterial ingredient from a new therapeutic class, bonded to a bait molecule comprising a functional group that can be cleaved by a beta-lactamase as defined in the classifications of Ambler (1980) and Bush and Jacoby (2010). The antibacterial ingredient is masked, and therefore inactive in the prodrug state, and regains its native structure and antibacterial properties once the prodrug has been cleaved in situ by the pathogenic bacteria.
Inventors:
HASSERODT JENS (FR)
SAMARUT JACQUES (FR)
BORDY MATHIEU (FR)
SAMARUT JACQUES (FR)
BORDY MATHIEU (FR)
Application Number:
PCT/EP2023/060405
Publication Date:
October 26, 2023
Filing Date:
April 21, 2023
Export Citation:
Assignee:
OSTA THERAPEUTICS (FR)
ECOLE NORMALE SUPERIEURE LYON (FR)
UNIV CLAUDE BERNARD UCBL (FR)
CENTRE NAT RECH SCIENT (FR)
ECOLE NORMALE SUPERIEURE LYON (FR)
UNIV CLAUDE BERNARD UCBL (FR)
CENTRE NAT RECH SCIENT (FR)
International Classes:
A61K31/546; A61K31/545; A61P31/04
Other References:
LINDSAY E. EVANS ET AL: "Exploitation of Antibiotic Resistance as a Novel Drug Target: Development of a β-Lactamase-Activated Antibacterial Prodrug", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 9, 22 April 2019 (2019-04-22), US, pages 4411 - 4425, XP055649177, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b01923
EVANS ET AL., J. MED. CHEM, vol. 62, 2019, pages 4411 - 4425
EVANS ET AL., J. MED. CHEM, vol. 62, 2019, pages 4411 - 4425
Attorney, Agent or Firm:
IP TRUST (FR)
Download PDF: